It might be the latest version of a long-term strategic policy approach, but stakeholders need to ask themselves a critical question. Are they willing to trade a bridging fund and process changes for a few health technologies, based on the promise it could accelerate access, in return for a disinvestment framework and deprioritising most new therapies?
Stakeholders deserve clarity on the strategic objective before this process gets underway
November 25, 2024 Latest NewsBioPharmaCommentLatest Video
New Stories
-
Five inspiring Australians recognised for their advocacy, support and care for people living with HIV
November 25, 2024 - - Latest News -
The journey of a word from high-level principle to specific policy proposals
November 25, 2024 - - Latest News -
Stakeholders deserve clarity on the strategic objective before this process gets underway
November 25, 2024 - - Latest News -
The 'Dispatched' Podcast - 22 November
November 22, 2024 - - Podcast -
Omico's Professor David Thomas receives NSW Premier’s Award for Outstanding Cancer Researcher
November 22, 2024 - - Latest News -
Medicines Australia says it has been and is still advocating against secrecy provisions
November 22, 2024 - - Latest News -
Another example of why the language used by government really matters
November 22, 2024 - - Latest News